kyphon- Innovative Osteoporosebehandlung - 500 Beiträge pro Seite

[Pontiuspilatus]

so hiermit ist der erste kyphon thread gestartet. Infos folgen in kürze

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.499.245 von Pontiuspilatus am 26.03.07 14:35:25

Sehr schön Pontius...jetzt haben wir bald für alle unserer Lieblinge einen Thread...
Osteoporose wird zur Volkskrankheit ähnlich Diabetes..
Gruss space

[spaceistheplace]

hier ein ganz kurzes Unternehmensportrait von der deutschen website:

Seit seiner Gründung im Jahr 1994 befasst sich das Unternehmen Kyphon mit der Verbesserung der Lebensqualität von Patienten mittels der Revolutionierung medizinischer Praktiken. Kyphon sieht seine Aufgabe darin, zum anerkannten, führenden Unternehmen bei der Wiederherstellung der Wirbelsäulenfunktion mittels minimal-invasiver Behandlungen zu werden. Wir wollen die Grundwerte wie Loyalität, Vertrauen und gegenseitige Achtung erhalten und unser Unternehmen auf der Grundlage von Aufrichtigkeit, Integrität und Engagement führen.

Der Hauptsitz von Kyphon befindet sich in Sunnyvale, Kalifornien, und das Unternehmen beschäftigt weltweit insgesamt über 850 Mitarbeiter. Die europäische Hauptgeschäftsstelle befindet sich in Brüssel, Belgien, und versorgt Europa, den Nahen und Mittleren Osten, Südafrika sowie den asiatisch-pazifischen Raum. Für mehr Informationen über die Unternehmensgeschichte und die Produkte sowie für Informationen für Investoren besuchen Sie bitte die Website von Kyphon Inc.: www.kyphon.com

[spaceistheplace]

guckt Euch mal die website an, dann wisst Ihr was Kyphon für eine innovative Technik zur Wirbelsäulenregeneration entwickelt hat.
GFruss space

http://www.kyphon-eu.com/de/index.htm

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.499.661 von spaceistheplace am 26.03.07 14:57:46

bin heute zur Börseneröffnung in den USA bei 44,95 eingestiegen..gut erwischt hoffentlich, die steigen sogar gerade gegen den Trend....
Gruss space

[spaceistheplace]

Video: Kyphon and the X-STOP(R) Procedure to be Featured on American Health Radio on Monday, April 2, 2007
New Minimally Invasive Procedure for Treating Lumbar Spinal Stenosis
PrintE-mailDisable live quotesRSSDigg itDel.icio.us

Last Update: 4:37 PM ET Mar 29, 2007


SUNNYVALE, Calif., March 29, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. (KYPH : kyphon inc com
News , chart , profile , more
Last: 45.59-0.14-0.31%

4:40pm 03/29/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
KYPH45.59, -0.14, -0.3%) today announced that Dr. James Zucherman, orthopaedic spine surgeon and medical director of the Spine Center at St. Mary's Hospital in San Francisco, and Julie Tracy, Kyphon's chief communications officer, will be interviewed together on American Health Radio, the nationally-syndicated health radio program hosted by Scott Broder. The program will include questions from listeners on the role of the X-STOP(R) Interspinous Process Decompression (IPD(R)) procedure to treat lumbar spinal stenosis.

To view the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/kyphon/27585/



During the show, Dr. Zucherman will discuss the treatment options available to patients suffering from lumbar spinal stenosis, including the X-STOP(R) device, the first FDA-approved interspinous process device for treating lumbar spinal stenosis. Symptoms from lumbar spinal stenosis often limit a patient's self-supporting daily activities, work, and social and recreational pursuits. Using a minimally invasive surgical procedure to place the X-STOP(R) implant, symptoms are relieved, and patients may return to a more active lifestyle.
The program will air live at 6:00 p.m. Central Time on Monday, April 2, 2007 and can be accessed at www.wrmn1410.com. A replay of the program will be available on Wednesday, April 4 at 8:00 p.m. Central Time and on Friday, April 6 at 6:00 p.m. Central Time. Repeat broadcasts will also available at www.healthradionetwork.com.
About the X-STOP(R) IPD(R) Procedure
The X-STOP(R) device represents a new approach to the treatment of lumbar spinal stenosis or LSS. LSS is a common spinal problem suffered mainly by the middle-aged and elderly population and results from a narrowing in the lumbar spinal canal that carries nerves to the legs. As this space in the lower spine shrinks, nerves are squeezed causing debilitating pain in the back and legs.
The X-STOP(R) system is the first approved Interspinous Process Spacer in the U.S. to treat LSS. It is designed to limit extension of the lumbar spine and keep the canal open in the lower spine that carries nerves to the legs thereby relieving pain associated with the narrowing of the canal.
Patients may experience rapid relief from their symptoms and enjoy improvement of physical function. The unique design of the X-STOP(R) implant enables it to be inserted using a minimally invasive approach, resulting in very little tissue disruption. Also, the X-STOP(R) implant's unique design allows it to be implanted without fixation to bones or ligaments so to provide a reversible procedure that should not limit future treatment options. Due to its minimally invasive nature, the procedure can typically be performed in less than an hour, and as demonstrated during the clinical trial, with a low rate of procedural complications.
According to an independent market research organization, there are approximately 1.4 million individuals in the United States with a primary or secondary diagnosis of lumbar spinal stenosis. The X-STOP(R) device may be a treatment alternative for approximately 220,000 of these individuals who would have otherwise been treated with conservative non-operative therapies or with a surgical procedure called a laminectomy.
About Kyphon Inc.
Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression procedure for treating lumbar spinal stenosis. More information about the company and its products can be found at www.kyphon.com and its patient education Web site, www.spinalfracture.com .
Functional Anaesthetic Discography is a trademark, and Kyphon, X-STOP, and IPD are registered trademarks, of Kyphon Inc.
SOURCE Kyphon Inc.
Investors and Media, Julie D. Tracy, Vice President, Chief Communications Officer of Kyphon Inc., [phone], [e-mail] http://www.kyphon.com Copyright (C) 2007 PR Newswire. All rights reserved

[Pontiuspilatus]

abgesehen davon das der kurs steigt gibts nix neues bei kyphon

[spaceistheplace]

Interessant ist der Chart. Wir befinden und jetzt an einem Widerstand, der sich seit Ende 2005 etabliert hat. Kommt der zu fall in nächster zeit, wovon ich überzeugt bin, machts nen Schub nach oben, ähnlich der Situation Mitte 2005, als die Kurse fast 2 jahre seitwärts liefen mit Deckel bei rd. 30 Dollar.
Diese aktuell rd. 47/48 Dollar hocken wie ein Deckel drauf, aber der Druck wird immer größer, dann fliegt er weg...
spannende Situation..im schlechtesten Fall kanns wieder bis 35 zurückgehen, dann wären Nachkäufe angesagt...
Gruss space

[Pontiuspilatus]

Kyphon erschien erstmals auf meinem radar als sie mitte 2005 diese explosion nach oben hingelegt haben. im november 2006 bin ich dann unmittelbar vor dem schub nach oben erstmals eingestiegen und halte die aktien jetzt ganz fest. vermutlich einer der medtech werte mit den grüßten wachstumsaussichten für die nächsten jahre.
Umsonst sind die nicht so teuer

Wenn der deckel wegfliegt gehts wahrscheinlich ganz schön nach oben kann durchaus bis 65 oder 70 springen.

[Pontiuspilatus]

und wenns zurück gehen sollte dann kauf ich auch nach

[spaceistheplace]

na Pontius, sollen wir rüber fliegen? istne tolle Gegend...

Kyphon Announces Annual Meeting Date and Record Date

SUNNYVALE, Calif., April 5, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Kyphon Inc. (Nasdaq: KYPH) today announced that it will hold its Annual Meeting of Stockholders on Thursday, June 14, 2007 at 2:00 p.m. PDT at its headquarters facility at 1221 Crossman Avenue, Sunnyvale, California. Kyphon stockholders of record at the close of market on April 20, 2007 will be entitled to vote at the meeting. Kyphon expects that proxy materials for the meeting will be mailed to stockholders in early May 2007.

About Kyphon Inc.

Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression procedure for treating lumbar spinal stenosis. More information about the company and its products can be found at www.kyphon.com and its patient education Web site, www.spinalfracture.com.

NOTE: Functional Anaesthetic Discography is a trademark, and Kyphon is a registered trademark, of Kyphon Inc.

KYPHG

SOURCE Kyphon Inc.

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.667.269 von Pontiuspilatus am 04.04.07 20:56:20

vermutlich einer der medtech werte mit den grüßten wachstumsaussichten für die nächsten jahre.

Das sehe ich genau so, Pontius. Man muss sich ja nur mal umscaheun, allein im Bekanntenkreis, wieviel Leute es mit der Wirbelsäule zu tun haben, die Leute werden immer jünger (allein 2 meiner Bekannten zw. 40 und 50 haben schon Operationen hinter sich) und auch Osteoporose nimmt stark zu. Ist auch alles kein Wunder bei zu wenig Bewegung, falsches Essen etc. pp...
das ist auch der Grund, warum ich mir SYNTHES gekauft habe, insbesondere wegen der künstl. Bandscheibe. da machen wir auf Sicht von 3-5 jahren nichts falsch!

Gruss space

[Pontiuspilatus]

Ja inzwischen haben ja sogar schon ein großteil der jugendlichen aufgrund zuwenig sport eine falsche Haltung was langfristig die Wirbelsäule schädigt. Und auch Osteoporose ist abhängig von Alter, Ernährung und Sport.

Naja mir als regelmäßigen Jogger und Schwimmer wird sowas vermutlich erspart bleiben
Kann nur jedem empfehlen regelmäßig zu sporteln um länger gesund zu bleiben. Nun ja wer nicht hören will (was ja sehr viele sind)muss dann halt irgendwann die dienste der Medtech Firmen in Anspruch nehmen.

Langfristig spricht alles für die Aktie könnte so sein als ob man Medtronic Anfang der 90er gekauft hat

Synthes machst auch nix falsch. Und bist sogar noch im SFr.

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.714.736 von Pontiuspilatus am 08.04.07 17:52:15

Ja, Pontius, gebe Dir recht! Ich jogge auch so 2-3 mal die Woche. das tut einfach gut, nicht nur körperlich, sondern auch für die Psyche! Und gerade von dort kommen auch Rückenprobleme...
Wollen wir hoffen, dass KYPH die MDT der Zukunft wird...

Gruss und einen schönen Feirtag
space

[Pontiuspilatus]

gena oder wie die alten römer schon sagten. mens sana in corpori sano (Gesunder geist in gesundem Körper)

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.733.212 von Pontiuspilatus am 09.04.07 22:30:42

ja, genau, aber viele handeln nicht danach...zu unseren Gunsten!
Gruss space

[Pontiuspilatus]

kyphon machts wirklich spannend. jetzt bräuchte es eine gute nachricht dann würde die aktie nach oben ausbrechen. mal sehn am 26.04 kommen die zahlen. wenn die gut ausfallen dürfte der deckel wegfliegen

[Pontiuspilatus]

achtung achtung alle anschnallen bitte der deckel fliegt grad weg

[spaceistheplace]

Antwort auf Beitrag Nr.: 28.842.962 von Pontiuspilatus am 16.04.07 19:46:27

jou Pontius, das sieht heute gut aus!!!!

[spaceistheplace]

Kyphon to Present at the Morgan Stanley Global Healthcare Unplugged Conference





SUNNYVALE, Calif., April 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Kyphon Inc. (Nasdaq: KYPH) today announced that Richard Mott, President and Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference at 11:00 a.m. Eastern Time on Wednesday, May 2, 2007, at the Ritz-Carlton Hotel, Key Biscayne, Florida.

A live audio webcast of the presentation will be available on Kyphon's corporate Web site at http://ir.kyphon.com. An archive of the presentation will be available for replay following the conference.

About Kyphon

Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression procedure for treating lumbar spinal stenosis. More information about the company and its products can be found at www.kyphon.com and its patient education Web site, www.spinalfracture.com.

Functional Anaesthetic Discography is a trademark, and Kyphon is a registered trademark, of Kyphon Inc.

KYPHG

SOURCE Kyphon Inc.

[Pontiuspilatus]

Press Release Source: Kyphon Inc.

Kyphon Reports First Quarter 2007 Operating Results
Thursday April 26, 4:38 pm ET
Revenues Grow 40% to $128.1 Million; St. Francis Integration Ahead of Schedule

SUNNYVALE, Calif., April 26 /PRNewswire-FirstCall/ -- Kyphon Inc. (Nasdaq: KYPH - News) today announced operating results for the first quarter ended March 31, 2007 as follows:

ADVERTISEMENT
Operating Results

Kyphon's worldwide net sales totaled $128.1 million, which includes $18.1 million of X-STOP® Interspinous Process Decompression (IPD®) product sales from the St. Francis Medical Technologies, Inc. (SFMT) acquisition that closed on January 18, 2007. Total product sales increased 40%, or 38% at constant foreign currency exchange rates, compared to the $91.4 million in net sales reported for the first quarter of 2006.

Total revenues in the U.S. increased 34% to $101.1 million, while total international revenues increased 70% to $27.0 million. Revenues from Kyphon's spinal motion preservation and disc disease diagnosis and therapies businesses, which includes the X-STOP® IPD®, Aperius(TM) Percutaneous Lumbar Interspinous Decompression (PercLID(TM)) and Functional Anaesthetic Discography(TM) (F.A.D.(TM)) technologies, were $14.3 million in the U.S. and $4.2 million in international markets.

Kyphon's core spinal fracture management and repair business revenue grew 20% to $109.6 million over the same quarter of 2006. Revenues in the U.S. grew 15% to $86.8 million and revenues from international operations grew 43% to $22.8 million in the first quarter.

Reported net loss was $22.6 million, or $0.50 per share compared to net income of $8.5 million, or $0.19 per diluted share, for the same period a year ago. The reported $0.50 loss per share includes $40.5 million pre-tax and $31.9 million after-tax SFMT in-process research and development (IPR&D) charges and acquisition-related expenses, which are detailed in the reconciliation of non-GAAP income below.

Non-GAAP diluted earnings per share for the first quarter of 2007 were $0.20, compared to diluted earnings per share of $0.19 in the same quarter a year ago. The non-GAAP diluted earnings per share of $0.20 excludes the following impacts from the SFMT acquisition: (1) $0.45 per share for IPR&D charges; (2) $0.09 per share for write-off of bank loan fees associated with the acquisition; (3) $0.05 per share for purchase accounting adjustments related to inventory valuation; (4) $0.03 per share for costs related to the transition of SFMT sales agent activities to Kyphon's direct sales force in the U.S.; and (5) $0.05 per share for severance and other transitional compensation expense. A reconciliation of GAAP and non-GAAP operating results is presented below.

"We are pleased with our strong execution this quarter and the focus that was maintained on our core spinal fracture management and repair business while integrating the X-STOP® IPD® system obtained through our St. Francis acquisition," said Richard Mott, president and chief executive officer of Kyphon. "We made excellent progress in assimilating St. Francis' operations into Kyphon's and undertaking clinical initiatives designed to support long term procedural adoption and adequate facility and physician reimbursement for the X-STOP® IPD® technology. Furthermore, as device competition increases in the vertebral compression fracture market, we believe the ability of balloon kyphoplasty to achieve deformity correction coupled with the growing body of clinical data for the procedure remain key considerations for many clinicians in selecting the appropriate treatment for their spinal fracture patients. We believe we are well positioned for future growth through our focus on restoring spinal function through minimally invasive therapies," Mott concluded.

Business Highlights

During the first quarter of 2007:

-- Kyphon completed enrollment for its Japan registry trial for its balloon kyphoplasty inflatable bone tamps and bone cement. This represents a critical milestone for obtaining regulatory approval in this key market with an estimated half-million fractures each year due to osteoporosis.

-- The health insurance company Aetna, Inc. published national coverage for kyphoplasty. Aetna's membership represents over 30 million covered lives, more than 767,000 health care professionals, and more than 453,000 primary care physicians at over 4,400 hospitals.

-- Kyphon successfully closed a $400 million offering of convertible senior notes. The proceeds, together with revolver borrowings, were used to retire the $425 million senior secured term loan incurred to complete the acquisition of SFMT.

-- Kyphon launched its Aperius(TM) PercLID(TM) system for the treatment of mild to moderate lumber spinal stenosis (LSS) in select European markets. The device received the CE Mark in October 2006 and is a percutaneous solution used by spine specialists in treating LSS.

-- Kyphon early concluded enrollment of patients in its European BEST (Biomaterials Effectiveness and Safety in Trauma) clinical trial for the use of its KyphOs(TM) FS calcium phosphate material in treating vertebral compression fractures caused by trauma. The clinical trial investigators determined that the interim analysis after enrolling 51 patients showed highly statistically and clinically significant improvement in pain in addition to having a high safety profile. The company is preparing to initiate market launch activities of KyphOs(TM) FS in select European countries in the second half of 2007.

-- Kyphon initiated enrollment in a pilot multi-center, prospective, single-arm clinical study evaluating its Discyphor(TM) Catheter for the F.A.D.(TM) procedure versus provocative discography. The SODA (Study Of Disc Anaesthesia) study is expected to enroll up to 100 patients in up to 15 sites and is designed to measure the proportion of positive disc levels registered after provocative discography differing from that after the F.A.D.(TM) procedure.

-- Kyphon enrolled 23 patients in its CAFE (CAncer Fracture Evaluation), study bringing the total cumulative enrollment to 75 patients. This multi- center, randomized, controlled study designed to evaluate balloon kyphoplasty versus non-surgical management in patients suffering vertebral compression fractures due to cancer is intended to enroll up to 200 patients.

-- Kyphon enrolled 30 patients in its KAVIAR (Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures) study, bringing the total cumulative enrollment to 45 patients. This multi-center, randomized, controlled study is designed to evaluate balloon kyphoplasty against vertebroplasty on a number of endpoints and is intended to enroll up to 1,234 patients.

Financial Outlook for Full-Year 2007 and Quarter Ending June 30, 2007

For the full-year 2007, net sales are targeted to increase approximately 40% to 43% versus 2006 to $570-$585 million. Based on our view of how our existing business is expected to perform, we are providing this updated target revenue range although it excludes all of the $5-10 million in 2007 revenue from the Disc-O-Tech products that was originally included in our previous guidance of $565-$585 million. The company presently assumes that both previously announced asset transactions with Disc-O-Tech Medical Technologies, Ltd. will close by the end of the fourth quarter of 2007; however, both remain subject to clearance by the Federal Trade Commission and the timing of the closing of these transactions remains uncertain.

We anticipate approximately 82% to 85% of 2007 revenues will be generated from our spinal fracture management and repair business and approximately 15% to 18% will be generated from our spinal motion preservation business, which includes the X-STOP® IPD® and the Aperius(TM) PercLID(TM) system. International revenues are expected to comprise approximately 22% to 24% of total 2007 revenues.

The full-year 2007 target range for earnings per diluted share, which includes the impact of all of the charges associated with the SFMT and Disc-O- Tech transactions except the write-off of IPR&D, is expected to be between $0.80 and $0.88. The target range for non-GAAP earnings per diluted share excluding IPR&D charges and the acquisition-related expenses as outlined in the GAAP to non-GAAP reconciliation provided below is $1.06 to $1.14. This target earnings range assumes amortization of intangible charges for the full year of $19 million related to the SFMT acquisition and $3 million relating to the Disc-O-Tech asset acquisition transactions.

The company estimates that the one-time pre-tax charge for IPR&D associated with the acquisitions of SFMT and the spinal assets of Disc-O-Tech will be approximately $56 million. Of the estimated $56 million charge, the $21 million associated with the SFMT acquisition recorded in the first quarter of 2007 is non-tax deductible. Kyphon currently assumes the remaining $35 million of the IPR&D charge relating to the two Disc-O-Tech transactions will occur in the fourth quarter of 2007.

For the second quarter of 2007, the company anticipates worldwide net sales of $137 million to $142 million, which represents an increase of 36% to 41% versus the second quarter of 2006. Worldwide net sales from the spinal fracture management and repair business are targeted to be between $114 million to $118 million, which represents an increase of 13% to 17% versus the same period a year ago. Net sales from the company's international operations are targeted to constitute approximately 22% to 23% of worldwide revenues in the second quarter of 2007.

For the second quarter of 2007, the target range for earnings per diluted share including the impact of certain acquisition related charges is $0.18 to $0.20. The non-GAAP earnings per diluted share, excluding the after-tax impact of certain acquisition-related expenses, estimated at $2.7 million pre- tax, is targeted to be between $0.21 and $0.23. A reconciliation of GAAP to non-GAAP earnings per diluted share for the company's financial outlook is as follows:

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.023.939 von Pontiuspilatus am 27.04.07 06:49:25

hier noch ne Zusammenfassung der Ergebnisse. In der darstellung von Dir Pontius muss man ja Buchhalterprofi sein, um das alles zu kapieren bzw. die Sondereinflüsse zu extrahieren etc. pp. In der Zusammenfassung unten ist es etwas auf den Punkt gebracht.
Wenn ich das richtig sehe, liegen die Ergebnisse im Rahmen der Erwartungen, evtl. leicht darunter, ebenso der Ausblick für 2007.
Es wird also heute rückwärts gehen in NYC. Da die Kurse in Frankfurt auf den Schlusskursen von NYC notieren, habe ich gerade erstmal verkauft. ich glaube, die sache ist mir doch ein bißchen zu heiß....sorry pontius...trotzdem danke für den Tipp. ich warte jetzt erstmal ein bißchen ab, was der Kurs so macht.
Zudem habe ich ja auch noch ISRG im Depot, die ja auch spekulativer ausgelegt sind...eine heißere Aktie reicht eigentlich aktuell.

Gruss space




Kyphon Q1 Adj. EPS Rises; Guides Q2, FY07 - Quick Facts



(RTTNews) - Thursday, Kyphon Inc. (KYPH) reported first quarter non-GAAP net income of $0.20 per share, compared to $0.19 per share in the same quarter last year. Analyst polled by First call/ Thomson Financial expected the company to report earnings of $0.03 per share.

The company's net loss for the quarter was $22.6 million or $0.50 per share, compared to net income of $8.5 million or $0.19 per share in the year ago period.

The company's recent quarter net loss included $40.5 million pre-tax and $31.9 million after-tax SFMT in-process research and development charges and acquisition-related expenses.

Net sales for first quarter rose to $128.13 million from $91.42 million in the year earlier quarter.

Looking ahead, the company expects second quarter GAAP earnings in range of $0.18-$0.20 per share, while non-GAAP net income is expected in the range of $0.21-$0.23 per share. Net sales for the quarter are expected to range between $137 million and $142 million.

Analysts expect the company to expect second quarter net income of $0.21 per share on $143.33 million.

Further ahead to the full year 2007, the company anticipates GAAP results in range of a loss of $0.05 per share to profit of $0.03 per share. Full year earnings, excluding in-process research and development, are expected in range of $0.80-$0.88 per share. Non-GAAP earnings are expected to range between $1.06-$1.14 per share. The company currently anticipates net sales in range of $570-$585 million.

Analysts expect full year earnings of $0.88 per share on revenues of $582.16 million for the full year.

[Pontiuspilatus]

sorry wegen der eher sehr finanzwirtschaftlichen darstellung. hatte heut früh einfach keine zeit zusammenzufassen

laut yahoo finance reichten die umsatzschätzungen von 126- 131 mio
da sind wir ziemlich in der mitte.
ergebnisse würd ich als inline einschätzen. hab aber keine ahnung was der markt draus macht.

ich riskiers mal und bleib drin. 40 % Wachstum sind ja nicht grad schlecht
Sondereffekte klammere ich mal aus der betrachtung aus

[Pontiuspilatus]

vorbörslich in Ny derzeit - 2%

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.030.522 von Pontiuspilatus am 27.04.07 14:42:39

heute werden die Märkte erstmal zurück gehen, die GDP-daten schauen nicht so gut aus und zudem immer noch Infaltionsdruck...
na ja, mal sehen, was KYPH heute macht...

Gruss space

[Pontiuspilatus]

reaktion der börse auf die zahlen ist sehr moderat. kein grund jedenfalls um beunruhigt zu sein. momentan ca -4 %

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.034.502 von Pontiuspilatus am 27.04.07 18:39:36

ja, pontius, ist wahrlich moderat, ich habe heute schiss gehabt, echt! Eigentlich mag ich Aktien mit hohen Volatilitäten und hohen Bewertungen / Erwartungen nicht so, mir ists moderater lieber.
ich werde Dich hier aber trotzdem begleiten..

Gruss space

[Pontiuspilatus]

ja hast ja auch wirklich pech gehabt mit graco. es sind immer die letzten erfahrungen die einen beim handeln leiten. passiert mir auch immer wieder. ok kyphon ist schon spekulativer als eine syk. aber das potential ist auch größer. wachstum ist echt ok gewesen. ein verlust sieht zwar auf den ersten blick nicht schön aus aber dieser kommt ja im fall von kyphon nur aufgrund der einmaleffekte zustande.

so wie ich das sehe haben die sogar das jahresziel beim umsatz leicht angehoben.

ich denk wenn du schaffst bei 45 für den gleichen betrag 10% mehr aktien zurückzukaufen ist die sache perfekt gelaufen

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.034.631 von Pontiuspilatus am 27.04.07 18:50:55

ich denk wenn du schaffst bei 45 für den gleichen betrag 10% mehr aktien zurückzukaufen ist die sache perfekt gelaufen
Ich könnte mir aber auch vorstellen, dass es noch weiter runter geht als 10%, vor allem wenn wir mal ne Korrektur bekommen, die Märkte sind in den letzten 4 Wochen für mich zu schnell nach oben gelaufen. Da könnte im Sommer schon mal ne Korrektur kommen. ich halte ein Pulver erstmal trocken...

Gruss space

[Pontiuspilatus]

klar kanns mehr als 10 korrigieren. Kommt halt immer auf die momentane situation des gesamtmarktes an. Ich geh mal davon aus das die kurse im sommer eher seitwärts laufen werden. einen einbruch wie letzten sommer halte ich für unwahrscheinlich.

[Pontiuspilatus]

bis jetzt hält sich kyphon jedenfalls phantastisch. ich geh davon aus das wir am jahresende wesentlich höher stehen

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.076.642 von Pontiuspilatus am 30.04.07 19:19:43

Kyphon hat auch Spendierhosen an...das wird jedenfalls den Bekanntheitsgrad fördern...

Gruss space

Kyphon Sponsors New 'Beyond Broken Bones' Exhibit at the International Museum of Surgical Science



Last Update: 4:15 PM ET May 3, 2007


SUNNYVALE, Calif., May 3, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. announced today that a new exhibit, "Beyond Broken Bones: The Story of Orthopedics and Prosthetics," will open on Saturday, May 5, 2007 at the International Museum of Surgical Science (IMSS) located at 1524 N. Lake Shore Drive, Chicago, Illinois.
The opening of the exhibit will be celebrated with a reception from 4:00 p.m. to 7:00 p.m. Central Time on May 5, 2007. This reception, sponsored by Kyphon, is free and open to the public, although RSVP is encouraged (312-642-6502 ext. 3130 or [e-mail]). Following the opening, this long- term exhibit will be on view at the Museum for at least three years.
"Beyond Broken Bones" tells the story of orthopedics and prosthetics -- from the mechanics and materials of the body's musculoskeletal system, to prosthesis design and surgical and non-surgical treatments for orthopedic conditions, as they developed from Ancient Egypt to the present.
Showcased in "Beyond Broken Bones" will be a broad range of artifacts, from archival documents and artworks representing orthopedic and prosthetic pioneers, to historical objects including ancient bone-cutting tools, Civil War amputation instruments, and early 20th-century artificial limbs. Several contemporary devices will be on display, and the exhibit will also feature case studies on modern and historical orthopedic conditions, as well as past and present therapies, including balloon kyphoplasty for treating spinal fractures caused by osteoporosis and cancer.
About the International Museum of Surgical Science

[Pontiuspilatus]

Investor's Business Daily
A Golden Age For Medicine
Friday May 4, 7:00 pm ET
Marilyn Much

It's no secret that getting old is a real drag.

As we move into our senior years, our bodies undergo a natural decline. Joints degenerate. We become more prone to back and heart problems, and our eyesight worsens.

ADVERTISEMENT
click here
With the U.S. population living longer, a lot of us are in that boat. That has increased demand for medical products and technology to treat orthopedic, cardiac, vision and other problems.

Members of IBD's Medical-Products industry group are a disparate lot, but they share a similar goal: to improve and enhance the quality of life for patients.

Take Kyphon (NasdaqGS:KYPH - News). It has developed a minimally invasive surgical procedure called balloon kyphoplasty to repair spinal fractures caused by osteoporosis or cancer. It also has a procedure to diagnose the source of lower back pain. Another preserves spinal motion.

Another player, StrykerSYK, makes artificial knees, hips and spinal implants and related surgical products.

Other major orthopedic firms include Wright Medical (NasdaqGS:WMGI - News) and London-based Smith & Nephew (NYSE:SNN - News).

The demographic shift will mean more patients, says Ed Shenkan, an analyst at Needham & Co.

"As the baby boomers get older, it's inevitable they're going to experience degeneration of joints, more pain in the back and more cardiac and respiratory problems," he said.

They also want to be able to walk and remain active in their later years, which stimulates demand for knee and hip replacements.

Eye care products maker Alcon (NYSE:ACL - News) also gets a lift from the growing number of seniors. Most of the market segments it addresses are products or drugs designed for people who have conditions in their 60s, 70s and 80s.

1. Business

The business is all about offering innovative products that meet doctors' and patients' needs.

Take Cytyc (NasdaqGS:CYTC - News), a maker of tests and treatments for female health problems.

Cytyc focuses on excellent execution, says Chief Executive Patrick Sullivan.

"One of the hallmarks of the company's business model is (offering) a best-in-class product," he said.

Cytyc is No. 1 in every category in which it competes, he says.

Its ThinPrep Pap test helps screen women for cervical cancer. Since it came to market in 1996, it has largely replaced the Pap smear test.

Cytyc ships about 36 million tests a year to labs and hospitals at "very attractive" margins, Sullivan says.

Alcon's diverse lineup includes ophthalmic surgical products such as those used during cataract surgery, drugs to treat diseases such as glaucoma, contact lenses and other related goods.

Alcon often launches new offerings in each segment, Chief Executive Cary Rayment says. About 66% of 2006 sales came from products introduced in the last 10 years.

One example: the AcrySof ReStor, an intraocular lens implanted after cataract surgery. Unlike previous lenses, it offers patients a full range of vision.

Kyphon also has an innovative platform. Its balloon kyphoplasty is the only balloon-based product on the market that can repair spinal fractures, the firm says.

Integra LifeSciencesIART makes surgical implants and medical instruments. Its products are used primarily in neurosurgery, extremities reconstruction, orthopedics and general surgery.

In neurosurgery, it's the U.S. market leader with offerings ranging from implants and instruments to monitoring systems, says Jack Henneman, executive vice president and administrative officer.

The company doesn't rely on any one product or technology.

"Our strategy is to give (our) customers whatever products make their lives easier," Henneman said. "Our goal is to have a diversified bag of products for each customer base."

Name of the game: The key, analyst Shenken says, is launching novel technological advancements that treat an unmet need of patients and physicians. Once these products get Food and Drug Administration approval, the company needs established distribution channels.

2. Market

The medical products field's two largest sectors, cardiovascular devices and orthopedics, have driven much of the strong growth over the past decade, Standard & Poor's analyst Robert Gold wrote in a report.

The worldwide orthopedic market is more than $20 billion, with about 66% of sales in the U.S., analyst Ben Andrew of William Blair & Co. says. He pegs the global cardiovascular market at between $20 billion and $25 billion. It also is heavy in the U.S., he says.

In 2006, sales growth in certain segments of orthopedics and cardiovascular devices slowed due to factors such as a lag in new product launches and pricing pressure, Gold said.

He sees the tide turning in 2007 as pricing pressures ease and procedure volume rises amid new products and rising demand for existing ones. He expects the orthopedics segment's unit volume to grow 11% from 2006.

Smith & Nephew's endoscopy division is the global leader in arthroscopy, which is minimally invasive surgery for articulating joints -- knees, shoulders, small joints like wrists and hips. It has about 25% of the about $2.2 billion market, the unit's president, Mike Frazzette, says.

The company's fastest-growing market is knee procedures, with hip procedures also expanding.

The spine market, where firms such as Kyphon and Medtronic (NYSE:MDT - News) compete, has been growing about 15% a year worldwide, analyst Shenken figures. He sees growth continuing at 10% to 15% annual rate, approaching $10 billion by 2010.

Key market drivers include rising adoption of minimally invasive therapies and spine surgeons' increased awareness and willingness to use novel technologies.

Gold sees a rebound in certain sectors of cardiology this year. The field's fastest grower had been the cardiac rhythm management segment. This market includes implantable cardioverter defibrillators, or ICDs.

In 2005 and 2006, the ICD segment was hurt by a series of product recalls by leading suppliers, including market leader Boston Scientific (NYSE:BSX - News). After a flat global ICD market in 2006, Gold expects the market to start growing again, by about 7% in 2007. He sees an 8% to 10% yearly rise through 2010.

3. Climate

According to the U.S. Census Bureau, the percentage of the total U.S. population age 65 and older will rise to 14.1% in 2010 from 10.9% in 2000.

"If you look at the health care market in general and the eye care market specifically, what's driving the long-term growth is the aging population," said Alcon's Rayment. "As the population throughout the world ages there will be increased demand for products and devices to improve or restore vision."

Cytyc's Sullivan sees another plus: "When you're in the health care business you're not going through the cyclical ups and downs you have with (the) steel and auto (fields)," he said. "People get sick and need medical attention and that doesn't change. I think the climate is excellent."

Still, challenges remain.

"We're in an environment where companies must substantiate the clinical value of their products and relate it to the price they charge for the product," said Needham & Co.'s Shenken. Payers are reluctant to foot the bill for new technology unless it's more effective and cuts costs, he says.

4. Technology

One category where Integra has a technological edge is in tissue engineering, Henneman says. About 30% of its business is in engineered collagen implants that regenerate or repair body tissue.

One such product is DuraGen, a graft used by brain surgeons to regenerate the dura mater, which is the membrane that contains the brain and spinal cord.

Other players work to come up with cutting-edge technology. In 2003, the FDA approved Cytyc's ThinPrep Imaging System. It's an interactive computer system that helps screen and diagnose ThinPrep Pap-test slides.

Last year, Smith & Nephew got approval for a hip-resurfacing implant system, the first such system in the U.S., analyst Gold wrote.

5. Outlook

All players should benefit from increased health care spending and the continued launch of innovative products.

A graying population also should fuel demand.

"In orthopedics, demographics and technology innovation are particularly strong catalysts for important categories, such as joint replacement and spinal repair," Gold wrote.

Upside: Frequent requests by doctors for minimally invasive technologies are another plus, Shenken says. Patients and health care payers like these procedures because they lead to better long-term outcomes.

Merger and acquisition activity has been strong and should continue in 2007, Gold adds. He expects this to create bigger competitors in orthopedics, vision care, interventional cardiology and other areas.

Risks: Few important new products, which typically help drive growth, will be launched in 2007, though Gold sees improvement in 2008 and 2009.

A change of power in Congress and the upcoming presidential election is a wild card for government health care reimbursements and new product approvals.

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.181.248 von Pontiuspilatus am 07.05.07 07:17:52

Danke, pontius, für den Bericht! Er drückt genau das aus, was wir schon gesagt haben. Vor allem die Demographie spricht für die Medtech-Branche. Das Wachstum ist in den nächsten jahren gesichert relativ unabhängig von der konjunkturellen Entwicklung.

Gruss space

[spaceistheplace]

hier was Aktuelles von heute zu Kyphon:

latest news [ECTX] ECtel's CFO Fainaro to leave for other opportunities

Zacks Analyst Blog Highlights: Kyphon, Biomet and Cardinal Health



Last Update: 6:00 AM ET May 7, 2007


CHICAGO, May 07, 2007 (BUSINESS WIRE) -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Kyphon, Inc.
See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673
Here are highlights from Friday's Analyst Blog:
Better Margin Outlook for KYPH
Kyphon, Inc. reported first quarter results better than our EPS (earnings per share) and revenue estimates. Although we have backed out any Disc-O-Tech revenue contribution in 2007, given the delayed closing now expected in fourth quarter 2007, our EPS estimates go up on a better margin outlook. Our target moves up to $58.00, or 53x our 2007 EPS estimate of $1.09 and 37x our 2008 EPS estimate of $1.56. Our recommendation remains a Buy.
The high level of sales growth reported in the first quarter 2007 (+40%), is likely to continue. We estimate sales growth of roughly 42% in 2007, compared to the year ago period. KYPH has only penetrated, according to management, 20-25% of the 300,000 U.S. annually diagnosed vertebral compression fracture cases. A similar level of diagnosed cases exists in Europe.
Kyphon competes against larger, well-capitalized companies in the orthopedics space. However, within the kyphoplasty/vertebroplasty spine niche, Kyphon has leading market share, approximately double vs. its nearest competitor. Leading vertebroplasty companies include Biomet (BMET : Biomet Inc
News , chart , profile , more
Last: 43.35-0.03-0.07%

4:15am 05/07/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
BMET43.35, -0.03, -0.1%) and Cardinal Health (CAH : Cardinal Health, Inc
News , chart , profile , more
Last: 70.75-0.13-0.18%

4:15am 05/07/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
CAH70.75, -0.13, -0.2%) .
See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
SOURCE: Zacks.com

[spaceistheplace]

und hier eine ausführliche Darstellung der Geschäft von KYPHON. Gibts auf deren website unter dem Link:

http://files.shareholder.com/downloads/KYPH/120414577x0x8639…

Es dauert ein bißchen, da es rd. 4 MB daten sind.

Gruss space

[spaceistheplace]

Kyphon to Present at the Citigroup Global Healthcare Conference



Last Update: 4:15 PM ET May 8, 2007


SUNNYVALE, Calif., May 8, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. today announced that Arthur Taylor, Chief Operating Officer, is scheduled to present at the Citigroup Global Healthcare Conference at 3:30 p.m. Eastern Time on Tuesday, May 22, 2007, at the Hilton New York Hotel, 1335 Avenue of the Americas, New York, New York.
A live audio webcast of the presentation will be available on Kyphon's corporate Web site at http://ir.kyphon.com. An archive of the presentation will be available for replay following the conference.

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.223.487 von spaceistheplace am 09.05.07 07:32:09

Hallo, ich habe gerade einen Moderator bei WO eingeschaltet, um diesen Thread auch mit der WKN, ISIN und dem Kürzel verlinken zu lassen, da man bisher den Thread nur über die Namenssuche gefunden hat und nicht über die WKN etc.
Ich hoffe, pontius, das ist in Deinem Sinne, denn Threads werden ja oft über die WKN gesucht. Man muss diese Funktion beim Erstellen eines Threads festlegen. Später ist es nicht mehr möglich.

Gruss space

[spaceistheplace]

Însider-Kauf von 20.000 Stück vor 3 tagen:

http://ir.kyphon.com/secfiling.cfm?FilingID=1181431-07-30877

[spaceistheplace]

latest news [RSTO] Restoration Hardware now sees Q1 rev of $142M

Kyphon Announces Investor & Analyst Meeting on May 17, 2007
Company to Open the NASDAQ Stock Market to Commemorate Five Years as Publicly-Traded Company


Last Update: 4:15 PM ET May 9, 2007


SUNNYVALE, Calif., May 9, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. today announced that it will host an investor and analyst meeting on Thursday, May 17, 2007. The formal portion of the meeting will take place from 12:30 p.m. to 2:00 p.m. Eastern Time at the NASDAQ MarketSite located at 4 Times Square, New York, New York. The company also announced that Richard Mott, president and chief executive officer of Kyphon, will preside over the opening bell of the NASDAQ Stock Market the same day at 9:30 a.m. Eastern Time.
Management team members from Kyphon participating in the investor & analyst meeting will be Mr. Mott; Karen Talmadge, Ph.D., executive vice president, co-founder and chief science officer; Art Taylor, chief operating officer; and Maureen Lamb, chief financial officer.
Before the start of the meeting, Kyphon will host a lunch reception beginning at 11:30 a.m. Eastern Time at the NASDAQ MarketSite. The meeting and webcast will begin promptly at 12:30 p.m. Eastern Time. For those planning to attend the meeting in person, you must pre-register by contacting Beverly Loveless at 408-548-5415 or at [e-mail] by Monday, May 14, 2007. Please note that we anticipate not being able to accommodate walk-up registrations or registrations after May 14, 2007.
Webcast and Conference Call Information
The formal portion of the investor & analyst meeting will take place from 12:30 p.m. to 2:00 p.m. Eastern Time. A simultaneous webcast of the meeting will be available from the Investor Relations section of the company's corporate Web site at http://ir.kyphon.com. The webcast will be archived on this site for a minimum of two months.
Interested parties may also access the meeting by dialing 1-800-361-0912 (U.S.) or 913-981-5559 (International) and enter the confirmation code 3604457. An audio replay of the meeting will be available beginning from 5:30 p.m. Eastern Time on Thursday, May 17, 2007, until 12:00 a.m. Eastern Time on Monday, June 18, 2007. To access the replay, dial 888-203-1112 (U.S.) or 719-457-0820 (International) and enter the confirmation code 3604457.
About the NASDAQ Stock Market Opening Bell
The NASDAQ Stock Market rings the opening bell at 9:30 a.m. Eastern Time and a live webcast of the NASDAQ Opening Bell will be available beginning at 9:20 a.m. Eastern Time at: http://www.nasdaq.com/reference/marketsite_about.stm. Viewers can scroll to the bottom of the page to access the MarketSite live webcam link. Windows Media Player is necessary to view the webcam.

[Pontiuspilatus]

auch kyphon wird nach dem rückgang wieder zunehmend interessant. ist mit sicherheit einen der wachstumsstärksten medtech gesellschaften der nächsten jahre.

geschätztes durchschnittswachstum der nächsten 5 jahre 33 %

[Pontiuspilatus]

kgv 2009 ca 24
kgv 2010 ca 17

okay ist bisschen weit in die zukunft geblickt. Der gewinnschätzungen könnten jedoch sogar noch konservativ sein wenn man das wachstum der letzten zeit anschaut

[Pontiuspilatus]

kyph hält sich erstaunlich gut auf hohem nivea. das lässt für die zukunft auf einiges hoffen

[Pontiuspilatus]

kyphon ist auch charttechnisch eine sehr interessante aktie. bewegt sich manchmal monatelang unter relativ geringen schwankungen seitwärts und dann gehts plötzlich an einem tag 30 oder 40 % rauf

so wie 2 tage nach meinem einstieg

[spaceistheplace]

Antwort auf Beitrag Nr.: 29.477.061 von Pontiuspilatus am 26.05.07 15:32:09

warum auch immer...hinterlässt jedenfalls seine Spuren...

Kyphon downgraded to "market perform"

Monday, June 18, 2007 8:47:40 AM ET
Wachovia Securities

NEW YORK, June 18 (newratings.com) - Analysts at Wachovia Securities downgrade Kyphon Inc (KYPH.NAS) from "outperform" to "market perform

[Pontiuspilatus]

The Best Bets in Bionic Investing
Med-tech companies that cater to baby boomers' orthopedic and cardiac needs could be on the cusp of a huge opportunity

by Alex Halperin

At the end of 2006, equity analysts were celebrating a miraculous year on Wall Street. M&A activity and impressive earnings boosted the Dow Jones industrial average past 12,000 for the first time. But not everyone joined the fun. While sectors including energy and utilities powered the broader Standard & Poor's 500-stock index in 2006, the health-care sector was a relative weakling. The S&P Health Care index rose 5.4% on the year, the worst performance of any major sector and well behind the S&P 500's 13.6% rise.

But 2007 tells a different story as the sector has shown signs of recovery, outpacing the booming market as the S&P Health Care index is up 8.2% year-to-date through May 18. But investors should remember that the sector is broad and quite diverse, and that some segments may hold greater promise for gains than others.
Joint Venture

One trend investors might like to focus on: companies that cater to the health needs of aging baby boomers. Within health care, one subsector well-positioned to gain from this particular population is health-care equipment, which includes companies that produce everything from cardiac devices to artificial joints.

The wear and tear on joints, hips, and spines is one of the most potentially lucrative areas of medicine as baby boomers aim to maintain active lifestyles into their 60s and beyond. Orthopedics consultant Robin Young, who has surveyed products that address these issues, says the winning companies will be those that can make widely used products like hip and knee replacements more comfortable.

Take Zimmer Medical (ZMH). The company's jet-powered stock—up almost 50% in the last year—has received support from its 2006 introduction of a knee implant designed to suit the female body, and analysts remain positive. Reducing the post-operative pain for women, the device is designed to enable women to remain more active than preexisting unisex models.

Beyond implants, Young suggests that regenerative cures may ultimately take market share from artificial additions. Osiris Therapeutics (OSIR), for one, is developing a stem cell therapy to regenerate cartilage in the knee, though this is likely years away from availability.
Spinal—and Extremities—Tap

Still within orthopedics, two other areas to watch are the spine and a catchall category: extremities.

Young says dozens of companies are involved in a "motion-preserving sweepstakes" to stave off the need for motion-constricting spinal fusion procedures. One leader is Kyphon (KYPH), which earlier this year purchased spinal device outfit St. Francis Medical, a company with an approved product for treating lumbar spinal stenosis, a lower back condition that can severely impede day-to-day life. However, with so many companies—many small and private—cueing up treatments for back conditions, Young says there will be plenty of failures even in a rapidly expanding space. "The key is [being] first to market," he says.

Until recently, orthopedic devices tended to focus on blockbuster areas like knees, hips, and spine. However, Young says more money is now going to "extremities," such as "shoulders and elbows and toes and fingers and wrists." One player is Wright Medical Group (WMGI), which has product lines for feet and shoulders, among other neglected parts.

[Pontiuspilatus]

noch ein bisschen und wir brechen die 50er marke. Das analysten geschreibsel halte ich für irrelevant. lass die ruhig up und downgraden. Wenn sie upgraden wollen sie verkaufen und wenn sie downgraden wollen sie kaufen

[Pontiuspilatus]

schade das ich jetzt allein hier investiert bin. heute jedenfalls wurde die 50 $ marke unter stark steigendem volumen gebrochen

[spaceistheplace]

das wird heute für einen weiteren Schub sorgen...
Pontius, Bin heute morgen mit ner kleinen Position zu 40 EUR wieder eingestiegen. Super antizyklisches Investment, kaufen zum Höchstkurs!!!!

Bist also in D nicht mehr alleine...

Gruss space

S&P: Kyphon to replace Triad on MidCap 400

By MarketWatch
Last Update: 6:33 PM ET Jul 23, 2007


SAN FRANCISCO (MarketWatch) -- Standard & Poor's said it will add Kyphon Inc. to the S&P MidCap 400 index Wednesday, replacing Triad Hospitals Inc.

[spaceistheplace]

Antwort auf Beitrag Nr.: 30.822.473 von spaceistheplace am 24.07.07 09:32:04

zudem, bei eine Marktkapitalisierung von aktuiell 2,5 Mrd. Dollar kann KYPH auch problemlos übernommen werden bei der aktuellen Fusionswelle. Zu J&J würde es vermutlich passen...
Dann wäre aber locker ein Aufschlag von 40% fällig...

Gruss space

[spaceistheplace]

Antwort auf Beitrag Nr.: 30.822.783 von spaceistheplace am 24.07.07 09:53:11

WAS NE MELDUNG GERADE!!!! Medtronic kauft Kyphon, 35% Aufschlag zur Aktie. pontius, heute Händereiben angesagt!!!!
Ist eigentlich außer pontius und mir noch einer von Euch investiert?

Vor 3 tagen schreibe ich noch, dass Kyphon auch übernommen werden könnte mit einer Marktkapitalisierung von 2,5 Mrd. Dollar und heute passiert es. Sabberlott! So kann man natürlich die aktuelle baisse locker überstehen.

pontius, was meinste, was machen wir? Aktie weiter halten? Kyphon hat ja wohl der Übernahme zugestimmt und dann dürfte da auch nicht mehr viel passieren im Kurs , oder?
Für mich ist es das erste mal, dass eine Firma, die ich im Depot habe übernommen wird. Hast Du da etwas Erfahrung?

Gruss space


Medtronic to Acquire Kyphon for $3.9 Billion
Combination to Drive Growth With Treatments for Debilitating Spinal Conditions


Last Update: 6:31 AM ET Jul 27, 2007



MINNEAPOLIS & SUNNYVALE, Calif., Jul 27, 2007 (BUSINESS WIRE) -- Medtronic, Inc. (MDT : Medtronic, Inc
News , chart , profile , more
Last: 50.92-0.70-1.36%

3:45am 07/27/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
MDT50.92, -0.70, -1.4%) and Kyphon (KYPH : kyphon inc com
News , chart , profile , more
Last: 53.68-0.90-1.65%

4:15am 07/27/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
KYPH53.68, -0.90, -1.6%) today announced that the companies have signed a definitive merger agreement under which Medtronic will acquire all of the outstanding shares of Kyphon for $71 per share in cash. The transaction, which was unanimously approved by the boards of directors of both companies, is valued at approximately $3.9 billion. This excludes $320 million in payments associated with the St. Francis Medical Technologies, Inc. and Disc-O-Tech Medical Technologies, Ltd. transactions.
The acquisition price represents a 32% premium over Kyphon's closing stock price on July 26, 2007 of $53.68 and a 35% premium over Kyphon's 30-day average trading price of $52.76 per share. The transaction, which is anticipated to close in the first calendar quarter of 2008, is expected to be neutral to Medtronic earnings in the first full fiscal year after closing and accretive thereafter. Medtronic expects the merger to yield significant revenue, cost and tax synergies.
"We expect our combination with Kyphon to help accelerate the growth of Medtronic's existing spinal business by extending our product offerings into some of the fastest growing product segments and enabling us to provide physicians with a broader range of therapies for use at all stages of the care continuum," said Art Collins, chairman and chief executive officer of Medtronic. "Importantly, the combination will also enable more patients of all ages to receive the benefits of modern, minimally invasive spinal treatments earlier in their care, with life-style friendly options that are simpler, faster and less invasive than many traditional surgical treatments.
"We have great respect for Rich Mott and his team and look forward to Kyphon's employees joining Medtronic at the close of the transaction. Kyphon's world-class, global sales force will play a central role in the continued development of our spinal business," Collins concluded.
"We are very enthusiastic about the opportunity to deliver outstanding value for our shareholders that fully reflects Kyphon's innovation and growth potential. This merger also combines two recognized industry leaders in spinal treatments," said Richard Mott, president and chief executive officer of Kyphon. "By merging our complementary strengths and collective resources into one organization, we will meaningfully increase our ability to ensure we meet the needs of our clinician customers around the world and the patients they serve. This combination also offers our employees the opportunity to become part of an organization with a shared vision and the depth of resources that are increasingly beneficial for sustained success in our industry. We look forward to working with Medtronic to complete the transaction quickly and seamlessly. Our board of directors believes that this acquisition is in the best interests of our shareholders, employees and other stakeholders and has unanimously voted to recommend that Kyphon shareholders vote in favor of it."
The two companies' product lines and geographic presence are highly complementary. While both companies have expertise in minimally invasive, highly effective treatments, Medtronic's spinal surgery focus has been on providing treatment options for younger patients who are suffering from scoliosis and degenerative disc disease in the cervical and lumbar spine. Kyphon's focus has been on treating older patients suffering from vertebral compression fractures and spinal stenosis. Together, the combined entity will be able to leverage its knowledge of modern fusion, dynamic stabilization, artificial disc replacement, biologics, vertebral augmentation, interspinous process decompression, disc disease diagnosis, navigation and minimally invasive techniques to serve patients with a broader variety of spinal disorders in order to alleviate pain and restore health for more patients.
The combined entity will also have a larger and expanded base of customers than Medtronic serves alone. Medtronic primarily serves orthopaedic and neurological surgeons who specialize in spinal surgery. Kyphon serves these same physicians and also has a significant customer base with interventional radiologists and interventional neuroradiologists.
The transaction will be financed by a combination of cash on the balance sheet and debt.
The transaction is subject to customary closing conditions, including approval by antitrust regulators as well as Kyphon shareholders.
Cleary Gottlieb Steen & Hamilton LLP is acting as legal advisor to Medtronic and Goldman, Sachs & Co. and Piper Jaffray are acting as financial advisors. Latham & Watkins LLP is acting as legal advisor to Kyphon and JPMorgan is acting as financial advisor.
Analyst Conference Call/Webcast
Medtronic and Kyphon will host an investor conference call (612-332-1210) later this morning at 7:30 a.m. central time (5:30 a.m. pacific time) to discuss the Kyphon acquisition. For complete instructions on how to participate in the conference call, or to listen to the live audio webcast or a replay of the webcast, please refer to the Investor Relations sections at http://www.medtronic.com or http://www.kyphon.com.

[spaceistheplace]

Antwort auf Beitrag Nr.: 30.874.825 von spaceistheplace am 27.07.07 12:42:38

und die aktuellen Quartalszahlen liegen auch noch klar über den Erwartungen!

Kyphon Reports Second Quarter 2007 Financial and Operating Results
Revenues Increase 43% from Q206 to $144.3 Million


Last Update: 6:40 ET Jul 27, 2007


SUNNYVALE, Calif., July 27, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. (KYPH : kyphon inc com
News , chart , profile , more
Last: 53.68-0.90-1.65%

6:36am 07/27/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
KYPH53.68, -0.90, -1.6%) today announced financial and operating results for the second quarter ended June 30, 2007 as follows:
Financial Results
Kyphon's worldwide revenues for the second quarter of 2007 totaled $144.3 million, an increase of 43%, or 41% at constant foreign currency exchange rates, over the $101.1 million in net sales reported for the second quarter of 2006. Total U.S. revenues for the quarter increased 36% to $110.7 million over the same period in 2006, while total international revenues increased 73% to $33.6 million.
Kyphon's core spinal fracture management and repair product revenue grew 19% to $120.6 million over the same quarter of 2006, with U.S. revenues growing 13% to $92.2 million and international revenues growing 46% to $28.4 million. Revenues from Kyphon's spinal motion preservation and disc disease diagnosis and therapies products, which include the X-STOP(R) IPD(R), Aperius(TM) Percutaneous Lumbar Interspinous Decompression (PercLID(TM)), and Discyphor(TM) Functional Anaesthetic Discography(TM) (F.A.D.(TM)) technologies, were $23.7 million, with U.S. revenues of $18.4 million and international revenues of $5.3 million. Total revenues for the second quarter of 2007 included sales of $22.7 million of the X-STOP(R) IPD(R) products from our acquisition of St. Francis Medical Technologies, Inc. (SFMT) in January 2007.
For the second quarter of 2007, reported GAAP net income was $11.0 million, or $0.23 per diluted share compared to net income of $9.5 million, or $0.21 per diluted share, for the same period a year ago.
Non-GAAP diluted earnings per share for the second quarter was $0.26 compared to $0.21 per diluted share in the same quarter a year ago. The non- GAAP diluted earnings per share of $0.26 excludes the following impacts from the SFMT acquisition that closed in January 2007: (1) $0.01 per share for purchase accounting adjustments related to inventory valuation, and (2) $0.02 per share for severance and other transitional compensation expense. A reconciliation of GAAP and non-GAAP operating results is presented below.
"We are very pleased with our performance during the second quarter, as increased procedural penetration delivered strong revenue growth for Kyphon," said Richard Mott, president and chief executive officer of Kyphon. "Our results continue to reflect strong clinician adoption and the value to patients of balloon kyphoplasty and the X-STOP(R) IPD(R) procedure. Additionally, we made solid progress on key initiatives designed to fuel future growth including the introduction of new marketing programs to supplement expansion of our global sales channel, training of new spine specialists in performing balloon kyphoplasty and the X-STOP(R) IPD(R) procedure, and increased enrollments for our clinical trial programs," continued Mott. "We believe our focused efforts to bring innovative minimally invasive based technologies to physicians and patients around the world are creating a foundation for continued long-term growth," concluded Mott.
For the first six months of 2007, Kyphon's worldwide revenues totaled $272.5 million, an increase of 42%, or 39% at constant foreign currency exchange rates, over the $192.5 million in net sales reported for the same period in 2006. Total U.S. revenues increased 35% to $211.8 million for the first half of the year, while total international revenues increased 72% to $60.7 million.
Kyphon's core spinal fracture management and repair product revenue grew 20% during the first half of 2007 to $230.3 million over the same period in 2006. U.S. revenues grew 14% to $179.0 million while international revenues grew 45% to $51.3 million. Revenues from Kyphon's spinal motion preservation and disc disease diagnosis and therapies products were $42.2 million, with U.S. revenues of $32.7 and international revenues of $9.5 million. Total revenues for the first six months of 2007 included sales of $40.8 million of the X-STOP(R) IPD(R) products from our acquisition of SFMT in January 2007.
For the first six months of 2007, reported net loss on a GAAP basis was $11.6 million, or $0.26 per share compared to GAAP net income of $18.0 million, or $0.39 per diluted share, for the same period a year ago.
Non-GAAP diluted earnings per share for the first six months of 2007 was $0.46, compared to $0.39 per diluted share for the same period a year ago. The non-GAAP diluted earnings per share of $0.46 excludes the following impacts from the SFMT acquisition: (1) $0.45 per share for in-process research & development (IPR&D) charges; (2) $0.10 per share for write-off of bank loan fees associated with the acquisition; (3) $0.06 per share for purchase accounting adjustments related to inventory valuation; (4) $0.04 per share for costs related to the transition of SFMT sales agent activities to Kyphon's direct sales force in the U.S.; and (5) $0.07 per share for severance and other transitional compensation expense. A reconciliation of GAAP and non-GAAP operating results is presented below.
Business Highlights

During the second quarter of 2007:
-- Kyphon reported that a record number of balloon kyphoplasty procedures
were performed in the U.S., increasing the hospital activity rate to a
record 3.8 procedures per active hospital account per month.

-- Kyphon reported that the first balloon kyphoplasty cases were completed
in India, Malaysia and Hong Kong, enhancing the company's global
presence with revenues derived from approximately 45 countries.

-- Kyphon reported that approximately 540 spine surgeons were trained to
perform the X-STOP(R) IPD(R) procedure in the U.S. during the quarter,
bringing the total number of spine surgeons trained to perform the X-
STOP(R) IPD(R) procedure in 2007 to 930. Additionally, the number of
active X-STOP(R) hospital accounts in the U.S. grew 49% in the second
quarter to 620 compared to the first quarter of 2007.

-- Kyphon confirmed Medicare physician reimbursement for the X-STOP(R)
IPD(R) procedure has been established in all 50 states. Additionally,
in April the Centers for Medicare & Medicaid Services (CMS) published
the proposed rule for inpatient DRG payment rates for fiscal 2008. CMS
proposed moving the X-STOP(R) IPD(R) procedure into a new, higher
paying DRG and discontinuing the new technology add-on payment. The
proposed payment represents an increase ranging from 20-81% depending
on hospital specific factors over the existing payment currently
associated with the X-STOP(R) IPD(R) procedure.

-- In July, CMS published the proposed 2008 Hospital Outpatient
Prospective Payment System (HOPPS) rule. With regard to balloon
kyphoplasty, the 2008 proposed payment represents an increase of
approximately 18% over the total existing payment currently in effect.
With regard to the X-STOP(R) IPD(R) procedure, the proposed 2008
outpatient setting payment represents an increase of approximately 21%
over the existing payment currently in effect. Additionally, the pass-
through payment for the X-STOP(R) IPD(R) device was proposed to be
extended through 2008. Finally, balloon kyphoplasty is to be added to
the Medicare list of approved Ambulatory Surgery Center (ASC)
procedures effective January 1, 2008.


Use of Non-GAAP Financial Measures
Kyphon management believes that investors may wish to consider the impact of certain charges to better understand short- and long-term financial trends in the company's operations and financial performance. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. In addition, Kyphon management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.
Reconciliation of GAAP and Non-GAAP Operating Results
Non-GAAP results for the three and six-month periods ended June 30, 2007 exclude certain expenses related to the acquisition of SFMT. This non-GAAP presentation is given in part to enhance the understanding of the company's historical financial performance and comparability between periods. In addition, the company believes that the non-GAAP presentation to exclude certain charges is relevant and useful information that will be widely used by analysts, investors, and other interested parties in the medical device industry. Accordingly, the company is disclosing this information to permit additional analysis of the company's performance. A reconciliation of Kyphon's non-GAAP operating results to its GAAP operating results for the three and six month periods ended June 30, 2007 follows (unaudited, in thousands, except per share amounts):
Kyphon Inc.
Reconciliation of GAAP and Non-GAAP Operating Results
(unaudited; in thousands, except per share amounts)



Three Months Ended Three Months Ended
June 30, 2007 June 30, 2006
----------------------------------- --------------

GAAP Adjustments Non-GAAP GAAP
-------------------------- -------- --------------

U.S. net sales $110,676 $- $110,676 $81,641
International
net sales 33,655 - 33,655 19,421
-------------------------- -------- --------------

Net sales 144,331 - 144,331 101,062

Operating costs and
expenses:
Cost of goods sold 19,493 (933)(3) 18,560 12,913
Research and
development 13,484 (733)(5) 12,751 9,931
Sales and marketing 63,780 (260)(4)(5) 63,520 48,649
General and
administrative 20,026 (356)(5) 19,670 14,496
Amortization of acquired
intangible assets 5,404 - 5,404 283

Total operating costs
and expenses 122,187 (2,282) 119,905 86,272

-------------------------- -------- --------------
Income from operations 22,144 2,282 24,426 14,790
Interest expense (3,046) - (3,046) -
Interest income and other,
net 1,088 - 1,088 2,080
-------------------------- -------- --------------

Income before income
taxes 20,186 2,282 22,468 16,870
Provision for income
taxes 9,210 801 10,011 7,390
-------------------------- -------- --------------
Net income $10,976 $1,481 $12,457 $9,480
-------------------------- -------- --------------
Net income per share
Basic $0.24 $0.03 $0.27 $0.21
-------------------------- -------- --------------
Diluted $0.23 $0.03 $0.26 $0.21
-------------------------- -------- --------------
-------------------------- -------- --------------

Weighted-average shares outstanding:
Basic 45,599 45,599 44,327
-------- -------- --------------
Diluted 47,818 47,818 46,221
-------- -------- --------------



Kyphon Inc.
Reconciliation of GAAP and Non-GAAP Operating Results
(unaudited; in thousands, except per share amounts)

Six Months Ended Six Months Ended
June 30, 2007 June 30, 2006
----------------------------------- --------------

GAAP Adjustments Non-GAAP GAAP
-------------------------- -------- --------------

U.S. net sales $211,783 $- $211,783 $157,153
International net
sales 60,685 - 60,685 35,337
-------------------------- -------- --------------

Net sales 272,468 - 272,468 192,490

Operating costs and
expenses
Cost of goods sold 38,996 (5,191)(3) 33,805 23,878
Research and
development 25,264 (1,348)(5) 23,916 18,237
Sales and marketing 127,496 (4,099)(4)(5) 123,397 94,035
General and
administrative 39,957 (2,754)(5) 37,203 28,064
Amortization of
acquired
intangible assets 9,819 - 9,819 566
In-process research
and development 21,300 (21,300)(1) - -
-------------------------- -------- --------------
Total operating
costs
and expenses 262,832 (34,692) 228,140 164,780
-------------------------- -------- --------------

Income from operations 9,636 34,692 44,328 27,710
Interest expense (15,449) 8,061(2) (7,388) -
Interest income and
other, net 2,123 - 2,123 4,203
-------------------------- -------- --------------

Income (loss) before
income taxes (3,690) 42,753 39,063 31,913
Provision for income
taxes 7,930 9,367 17,297 13,940
-------------------------- -------- --------------
Net income (loss) $(11,620) $33,386 $21,766 $17,973
-------------------------- -------- --------------

Net income (loss)
per share:
Basic $(0.26) $0.73 $0.48 $0.41
-------------------------- -------- --------------
Diluted $(0.26) $0.72 $0.46 $0.39
-------------------------- -------- --------------

Weighted-average
shares outstanding:
Basic 45,426 45,426 44,181
-------- -------- --------------
Diluted 45,426 47,582 46,091
--------- -------- --------------

(1) In-process research and development (IPR&D) charges related to SFMT
acquisition.
(2) The write-off of loan fees related to the temporary bank financing
used to close the SFMT transaction.
(3) Purchase accounting adjustments related to inventory valuation for
SFMT.
(4) Costs related to the transition of SFMT agents to Kyphon's direct
sales force in the U.S.
(5) Severance and other transitional compensation expense related to the
SFMT acquisition.


Kyphon's operating results on both a GAAP and non-GAAP basis include stock-based compensation expenses of $6.8 million and $6.9 million for the three-month periods ended June 30, 2007 and 2006, respectively, and $13.4 million and $13.3 million for the six-month periods ended June 30, 2007 and 2006, respectively.
Earnings Call Information
Due to Kyphon's announcement earlier today of its execution of a definitive agreement to be acquired by Medtronic, no conference call will be held to discuss these results.
About Kyphon Inc.
Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) (F.A.D.(TM)) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression (IPD(R)) procedure for treating the symptoms of lumbar spinal stenosis. More information about the company and its products can be found at http://www.kyphon.com and its patient education Web site, http://www.spinalfracture.com.
Kyphon, KyphX, X-STOP and IPD are registered trademarks, and Aperius, PercLID, Discyphor, Functional Anaesthetic Discography and F.A.D. are trademarks, of Kyphon Inc.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements include, but are not limited to, those that use words such as "believes," "anticipates," "targets," "intends," "plans," "may," and words of similar effect, and specifically include the company's anticipated business direction and performance. Forward-looking statements are based on management's current preliminary expectations without taking into account any possible impact from the announced transaction with Medtronic or any other future strategic transaction and are subject to risks, uncertainties and assumptions, which may cause the company's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect Kyphon, its business and its financial results are detailed in the company's periodic filings with the Securities and Exchange Commission (SEC), including, but not limited to, those risks and uncertainties listed in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors Affecting Future Operating Results," which can be found in Kyphon's annual report on Form 10-K for the year ended December 31, 2006 filed with the SEC on February 28, 2007 and on Form 10-Q for the quarter ended March 31, 2007 filed with the SEC on May 10, 2007. Kyphon undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.
KYPHE



KYPHON INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited; in thousands, except per share amounts)

Three Months Ended Six Months Ended
June 30, June 30,
--------------- ----------------
2007 2006 2007 2006
---- ---- ---- ----

U.S. net sales $110,676 $81,641 $211,783 $157,153
International net sales 33,655 19,421 60,685 35,337
-------- -------- -------- --------
Net sales 144,331 101,062 272,468 192,490
-------- -------- -------- --------

Operating costs and expenses:
Cost of goods sold 19,493 12,913 38,996 23,878
Research and development 13,484 9,931 25,264 18,237
Sales and marketing 63,780 48,649 127,496 94,035
General and administrative 20,026 14,496 39,957 28,064
Amortization of acquired
intangible assets 5,404 283 9,819 566
In-process research and development - - 21,300 -
-------- -------- -------- --------
Total operating costs and
expenses 122,187 86,272 262,832 164,780
-------- -------- -------- --------

Income from operations 22,144 14,790 9,636 27,710
Interest expense (3,046) - (15,449) -
Interest income and other, net 1,088 2,080 2,123 4,203
-------- -------- -------- --------
Income (loss) before income taxes 20,186 16,870 (3,690) 31,913
Provision for income taxes 9,210 7,390 7,930 13,940
-------- -------- -------- --------

Net income (loss) $10,976 $9,480 $(11,620) $17,973
-------- -------- -------- --------

Net income (loss) per share:
Basic $0.24 $0.21 $(0.26) $0.41
-------- -------- -------- --------
Diluted $0.23 $0.21 $(0.26) $0.39
-------- -------- -------- --------

Weighted-average shares outstanding:
Basic 45,599 44,327 45,426 44,181
-------- -------- -------- --------
Diluted 47,818 46,221 45,426 46,091
-------- -------- -------- --------



KYPHON INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited; in thousands)

June 30, December 31,
2007 2006
---------- ----------
Assets
Current assets:
Cash and cash equivalents $51,868 $81,939
Investments - 120,214
Accounts receivable, net 97,157 73,859
Inventories 18,603 11,869
Prepaid expenses and other current assets 9,802 7,520
Deferred tax assets 15,985 6,072
---------- ----------
Total current assets 193,415 301,473

Property and equipment, net 37,179 27,590
Goodwill 357,944 4,802
Other intangible assets, net 205,042 9,940
Deferred tax assets - 14,955
Other assets 114,055 69,846
---------- ----------
Total assets $907,635 $428,606
---------- ----------


Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $14,073 $10,447
Accrued liabilities 76,716 62,980
---------- ----------
Total current liabilities 90,789 73,427
---------- ----------

Deferred rent and other 16,991 10,479
Borrowings 401,275 -
Deferred tax liabilities 62,449 -
---------- ----------
Total liabilities 571,504 83,906
---------- ----------

Commitments and contingencies

Stockholders' equity:
Common stock, $0.001 par value per share 46 45
Additional paid-in capital 287,481 284,672
Treasury stock, at cost (201) (201)
Accumulated other comprehensive income 2,408 1,607
Retained earnings 46,397 58,577
---------- ----------
Total stockholders' equity 336,131 344,700
---------- ----------

Total liabilities and stockholders' equity $907,635 $428,606
---------- ----------


SOURCE Kyphon Inc.

[Larry.Livingston]

Antwort auf Beitrag Nr.: 30.874.825 von spaceistheplace am 27.07.07 12:42:38

Verdammt und ich wollte heute abend einsteigen!!

[uraltkali]

Antwort auf Beitrag Nr.: 30.874.825 von spaceistheplace am 27.07.07 12:42:38

Hallo space und pontius;

ja, ich

gruss uraltkali

[Pontiuspilatus]

@space

da kam dein wiedereinstieg gerade zur richtigwn zeit
Meine gratulation
Als ich in kyphon einstieg (ende letzten jahres gings 1- 2 tage später auch ca 30 % rauf) Naja manchmal hat man einfach glück.

Ich finde es schade das kyphon geschluckt wird. Die aktie hätte langfristig riesiges potential gehabt. Das hat auch medtronic erkannt auf sicht von 2-3 jahren sind das schnäppchenkurse.

ich halte die aktie auf jedenfall. folgende gründe.
du bekommst zum termin der übernahme (soweit ich weis irgendwann anfang 2008) sicher 71 $. kurs notiert momentan bei ca 66 $. für die paar monate ist die differenz zwischen 66 und 71 eine schöne sichere verzinsung.
Es könnte sogar sein das jnj oder ein anderer medtech riese ein gegengebot vorlegt das höher als das von mdt ist. vielleict bietet jnj ja nächste woche schon 80 $

ich bin bis ende 2007 in der speku frist. ich verkaufe vor ablauf dieser sicher nicht (müsste sonst ca 100 % kursgewinn versteuern)
und hoffe das der übernahmetermin erst nach ablauf meiner spekufrist ist.

Du könntest auch verkaufen da du auch zum zeitpunkt der barabfindung noch in der spekufrist bist, so das du in jedem fall steuerpflichtige kursgewinne erzielen wirst.

Kommt halt darauf an ob du das geld momentan für einen anderen wert brauchst dem du bis zum zeitpunkt der übernahme kyphons sicher ien höheres prozentuales kurspotential zutraust als das bei kyphon von 66 auf 71. Wenn das der fall ist würde ich verkaufen. Bei kyphon jedenfalls hast du die % sicher

[Pontiuspilatus]

muss jetzt zu suchen anfangen wo ich das freiwerdende geld anlegen soll. vermutlich kauf ich für den halben betrag mdt, die andere hälfte lege ich in einem jüngerem wachstumsstärkeren medtech unternehmen an. habe einige kandidaten im auge. genaueres sage ich aber noch nicht

[spaceistheplace]

Antwort auf Beitrag Nr.: 30.904.243 von Pontiuspilatus am 29.07.07 00:25:45

pontius, danke für Dein statement. Ja, ich hatte echt Glück bzw. ein gutes Händchen, dass ich wiedereingestiegen bin, auch wenn der Kurs 10% höher war als bei meinem Ausstieg.
Also ich glaube, dass ich nicht verkaufen werde aktuell, außer die Aktie geht bis auf 70 oder so. Vielleicht spielt ja uns auch der Dollar noch ein paar Prozentchen in die Tasche bis 2008.
Ich habe auch schon gedacht, schade, dass KYPH gekauft wird. Allein schon die guten Quartalszahlen hätten am Freitag. 5-10% gebracht...Langfristig hätten wir mehr verdient und MDT wird wohl kaum so ne Performance hinlegen. MDT ist jedenfalls ne rel. sichere bank und absolut "ass" (=abgeltungssteuersicher wir zeigen unseren Finanzheinis in Berlin unseren A....). Da kann bzw. sollte man invetiert sein.

Gruss space

[spaceistheplace]

Antwort auf Beitrag Nr.: 30.902.486 von uraltkali am 28.07.07 21:59:33

uraltkali, Du bist auch in KYPH? Ich frage, weil Du hier noch nicht gepostet hast. Wenn ja, Glückwunsch!

Gruss space

[Larry.Livingston]

Antwort auf Beitrag Nr.: 30.910.966 von spaceistheplace am 29.07.07 10:27:40

Vielleicht sollte ich doch noch ein paar Kyphon kaufen. Dei (Minimum) $5 sind ja immerhin ziemlich sicher drin. Das wäre schon ein netter kleiner Zugewinn. Aber ich sehe das richtig, dass der genaue Barabfindungstermin noch nicht näher benannt ist? Dann müsste man sich wirklich die Differenz zum TG ausrechnen.
Und wenn JnJ jetzt mitbieten sollte auch gut, profitieren die halt. Die hab ich nämlich auch noch im Depot rumliegen.

[uraltkali]

Antwort auf Beitrag Nr.: 30.910.966 von spaceistheplace am 29.07.07 10:27:40

Hallo space,

Ja ich bin auch dabei, aber ich habe nicht gepostet, weil ich über diesen wert nicht viel weiss und bevor ich nur labere, schweige ich lieber. Es gibt unternehmen, mit denen ich mich intensiv beschäftige - und da gebe ich auch meine meinung ab.
Ich habe auf gut vertrauen gekauft, aufgrund eines tips von einem guten, vertrauensvollen bekannten.

Manchmal mache ich soetwas schon, ähnlich wie bei syk. Ich konnte deine empfehlung nachvollziehen und war sicher, dass es sich um eine qualitätsaktie handelt.

schönen gruss und ein schönes restliches wochenende, uraltkali

[spaceistheplace]

mit 65,60 Dollar liegt ja jetzt der Kurs fast 10% unter den 71 Dollars, die MDT bezahlen will. Also bis Anfang 2008, also so 6-7 Monate ist das keine schlechte Verzinsung, denke ich. Sollte z.B. noch ein feindliches Übernahmeangebot dazu kommen, dann ist es gar ein Schnäppchen. Ich werde mir heute in NYC noch ein paar Teile dazu kaufen.

Gruss space

[Pontiuspilatus]

ich stimme dagegen

Kyphon Sets Date for Shareholder Vote
Friday September 7, 10:53 am ET
Kyphon Shareholders to Vote on Takeover by Medtronic on Oct. 16

SUNNYVALE, Calif. (AP) -- Spinal implant maker Kyphon Inc. said Friday its stockholders will vote Oct. 16 on the company's proposed acquisition by medical device maker Medtronic.

Directors of both companies already unanimously approved the $3.9 billion deal, which was announced in July, and now need the nod from Kyphon shareholders.

Upon approval by antitrust regulators and Kyphon's stockholders, the deal is expected to be completed in the first quarter of 2008.

Kyphon develops and markets medical devices designed to restore and preserve spinal function. Medtronic focuses on heart defibrillators and pacemakers, but its spinal business has been growing.

In morning trade, shares of Sunnyvale, Calif.-based Kyphon rose 3 cents to $67.05, while shares of Medtronic, based in Minneapolis, fell 45 cents to $53.64.

[Pontiuspilatus]

welches ist eigentlich der genaue übernahmekurs??
Kyphon dürfte mit 69,65 jetzt schon sehr nahe dran sein.
ich glaub es waren 72 oder??

[spaceistheplace]

Antwort auf Beitrag Nr.: 31.683.206 von Pontiuspilatus am 21.09.07 09:16:00

Ja, wir sind schon sehe sehr nahe dran, 71 Dollar will MDT zahlen. Allein der schwache Dollar hält mich noch ab zu verkaufen gerade, ich hatte ja bei 64 Dollar noch mal nen Sack voll gekauft nach der Übernahmemeldung....

MEDTRONIC kauft KYPHON für 3,9 mrd. US-Dollar / Übernahme soll Wachstum bei Therapien für schwere Wirbelsäulenleiden ankurbeln
Minneapolis und Sunnyvale, CA. (ots) - Medtronic, (Nachrichten/Aktienkurs) Inc. (NYSE: MDT)
und Kyphon (Nachrichten) (NASDAQ: KYPH) haben angekündigt, dass Medtronic das
gesamte in Umlauf befindliche Aktienkapital von Kyphon zum Preis von
71 US-Dollar je Aktie erwerben wird. Der Wert der vertraglich
besiegelten Transaktion, die von den Führungsgremien beider
Unternehmen einstimmig befürwortet wurde, wird auf etwa 3,9
Milliarden US-Dollar beziffert. Darin sind weitere Zahlungen in Höhe
von 320 Millionen US-Dollar im Rahmen von Transaktionen mit St.
Francis Medical Technologies, Inc. und Disc-O-Tech Medical
Technologies, Ltd. nicht enthalten.

Der Kaufpreis liegt damit 32 Prozent über dem Aktienkurs von
Kyphon bei Börsenschluss am 26. Juli 2007 von 53,68 US-Dollar. Er
liegt um 35 Prozent über dem durchschnittlichen Kurs der Kyphon-Aktie
in den letzten 30 Tagen von 52,76 US-Dollar. Die Transaktion soll im
ersten Quartal 2008 vollständig abgeschlossen sein. Im ersten
Geschäftsjahr nach Abschluss der Transaktion wird sie sich
voraussichtlich neutral und danach positiv auf das Ergebnis von
Medtronic auswirken. Medtronic erhofft sich von dem Zusammenschluss
beträchtliche Synergieeffekte bei Erlösen, Kosten und Steuern.

"Wir gehen davon aus, dass der Zusammenschluss mit Kyphon das
Wachstum in unserem Wirbelsäulengeschäft beflügeln wird, indem wir
unser Produktangebot in einige der am schnellsten wachsenden
Produktsegmente ausdehnen und wir auf diese Weise Ärzten eine größere
Palette an Therapien auf allen Stufen der Versorgungsleiter anbieten
können", sagte Art Collins, Vorstandsvorsitzender und CEO von
Medtronic.

[spaceistheplace]

Die blicken doch gar nix, die Analos....wir sind noch 1,20 Dollar vom Übernahmepreis weg und dann kommt da so eine Aussage...
Für uns Deutsche kommt da ja nocht die Dollargeschichte dazu. pontius, Du bist doch auch drin, was machst Du? Auf nen steigenden Dollarspekulieren? mehr ist es eigentlich nicht. Bzw. hast Du ne Ahnung, wie das abläuft, wenn wir ausbezahlt werden nächstes Jahr? Sind da Gebühren fällig? ich habe keine Ahnung, für mich ist der Fall Premiere.

Gruss space

Kyphon downgraded to "market perform"

Monday, September 24, 2007 11:59:33 AM ET
Piper Jaffray

NEW YORK, September 24 (newratings.com) - Analysts at Piper Jaffray downgrade Kyphon Inc (KYPH.NAS) from "outperform" to "market perform."

[Pontiuspilatus]

also ich stimme erst mal gegen die übernahme. kyphon ist ne perle und mdt bekommt diese quasi geschenkt.

mit sehr hoher wahrscheinlichkeit geht die übernahme aber durch. in dem fall habe ich nicht vor bis nächstes jahr zu warten. sobald ich aus dem spek zeitraum raus bin steig ich aus und kassiere meine 100 % gewinn. dann lege ich vermutlich 50 % des betrages in mdt an und 50 % in einen anderen spekulativeren schnell wachsenden medtech wert

[spaceistheplace]

Solche DEppen...lassen sich echt die Kursgewinne für die nächsten Jahre entgehen...Hoffentlich haben nicht zu viele schon verkauft und bereits in MDT investiert. Die wurden dann erst mal kalt erwischt vorgestern...

Gruss space


Kyphon Stockholders Approve Merger with Medtronic

Last Update: 6:24 PM ET Oct 16, 2007
PrintPrint EmailE-mail Subscribe to RSSSubscribe to RSS DisableDisable Live Quotes
SUNNYVALE, Calif., Oct 16, 2007 /PRNewswire-FirstCall via COMTEX/ -- Kyphon Inc. announced today that its stockholders approved the adoption of the merger agreement with Medtronic, Inc. at a special meeting of stockholders held today.
As previously announced, on July 26, 2007, Kyphon entered into a definitive merger agreement with Medtronic, pursuant to which Medtronic agreed to acquire all of the outstanding shares of Kyphon common stock for $71.00 per share in cash. Consummation of the transaction remains subject to customary closing conditions, including clearance from antitrust authorities in Portugal and Turkey. The initial review periods in both of these jurisdictions are scheduled to expire later this month unless the antitrust authorities extend the relevant periods. The parties intend to consummate the transaction reasonably promptly following the receipt of the required antitrust clearances in Portugal and Turkey and the satisfaction of the other customary closing conditions contained in the merger agreement, but in no event prior to November 1.

[Pontiuspilatus]

solche deppen

ja so kann man es wirklich nennen. Kyph ist ja inzwischen durch die fast vollendete übernahme richtig langweilig da der kurs nur mehr minimal schwankt.

naja bin auch dort bald aus dem spekuzeitraum. 100% gewinn im jahr sind ja auch nicht schlecht. ich bin jedenfalls sehr zufrieden.

hab schon einige medtechwerte gecheckt und hab schon meine favoriten

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.171.484 von Pontiuspilatus am 27.10.07 09:59:34

Tja, Kyph ist ne reine Dollarspeku geworden....ich bekomme es eh mit dem Spekuzeitraum nicht hin, daher werde ich irgendwann verkaufen, ich hoffe ja immer noch auf ne kleine Ggenreaktion des Dollarsvilleicht mal auf 1,37 oder so. Nur das hält mich ab...


hab schon einige medtechwerte gecheckt und hab schon meine favoriten

Dann sag mal.... oder per PM....

Gruss space

[spaceistheplace]

Die Kyphon-Übernahme scheint jetzt doch schon vollzogen zu sein, oder pontius? Jedenfalls kan man die KYPH-Aktie in NYC nicht mehr handeln. Ich habe aber noch keine Post oder ähnliches von meiner Bank erhalten, Du? Mal sehen, wie lange das noch dauert...

Gruss space

04.11.2007
11:10

Medtronic und Kyphon schliessen Übernahme ab / Wachstum bei Therapien für schwere Wirbelsäulenerkrankungen erwartet

Düsseldorf (ots) - Medtronic, Inc. (NYSE:MDT) hat die Übernahme
von Kyphon Inc. abgeschlossen. Wie das Unternehmen mitteilte, werden
den Aktionären von Kyphon gemäß der am 27. Juli 2007 geschlossenen
Übernahmevereinbarung 71 US-Dollar in bar für jede ordentliche
Kyphon-Aktie gezahlt, die sie halten. Einschließlich der Schulden von
Kyphon beträgt das Volumen der Transaktion rund 4,2 Milliarden
US-Dollar. Medtronic hat die Transaktion überwiegend aus liquiden
Barmitteln finanziert.

"Die Produktportfolios und die geographische Präsenz beider Firmen
ist in hohem Maße komplementär", sagte der
Medtronic-Vorstandsvorsitzende Bill Hawkins. "Wir erwarten, dass
diese Akquisition helfen wird, das Wachstum von Medtronics
Wirbelsäulen-Geschäft zu beschleunigen, indem sie unser Angebot in
einem der am schnellsten wachsenden Segmente ausweitet und es uns
ermöglicht, Ärzte in größerem Umfang mit Therapien in allen Stadien
der Behandlung zu beliefern."

Richard Mott, Vorstandsvorsitzender von Kyphon, sagte: "Wir freuen
uns sehr, unseren Aktionären einen hervorragenden Wert zu bieten, der
Kyphons Innovations- und Wachstumspotential widerspiegelt. Die
Kombination unseres Geschäfts mit dem von Medtronic Spinal ist auch
für unsere Kunden, ihre Patienten und unsere Mitarbeiter von Vorteil.
Als Teil der Medtronic-Organisation werden wir besser in der Lage
sein, die Anforderungen unserer Kunden in den Kliniken und der
Patienten, die sie betreuen, mit unseren Technologien gerecht zu
werden. Unsere Mitarbeiter können Teil einer größeren Organisation
mit gleichen Werten werden, in der sie neue berufliche
Aufstiegschancen haben."

Wie Medtronic weiter mitteilte, hat Kyphon den Erwerb der nicht
mit Vertebroplastie befassten Unternehmensteile der Disc-O-Tech
Medical Technologies Ltd abgeschlossen. Außerdem wurde eine
definitive Vereinbarung getroffen, alle Unternehmensteile zu
verkaufen, die mit der Confidence-Produktlinie von Disc-O-Tech in
Verbindung stehen. Der Käufer dieser Confidence-Unternehmensteile hat
sich zur Übernahme aller Zahlungsverpflichtungen bereit erklärt, die
Kyphon bei der Vereinbarung zum Kauf dieser Firmenteile eingegangen
war. Die Verkaufsvereinbarung ist ihrerseits Gegenstand von
behördlichen Genehmigungen und an geschäftsübliche Bedingungen
geknüpft.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.311.287 von spaceistheplace am 06.11.07 17:12:00

Gestern haben eine ganze Reihe KYPHONer ihre Aktien hergegeben bzw. an MDT verkauft. Damit ist das Kapitel Kyphon wohl beendet, zumindest, was die Eigenständigkeit als Firma angeht.

Gruss space

[Pontiuspilatus]

Die Kyphon-Übernahme scheint jetzt doch schon vollzogen zu sein, oder pontius? Jedenfalls kan man die KYPH-Aktie in NYC nicht mehr handeln. Ich habe aber noch keine Post oder ähnliches von meiner Bank erhalten, Du? Mal sehen, wie lange das noch dauert..

ne ebenfalls noch nicht. aktie ist nicht mehr handelbar.
ich hoff mal die lassen sich noch 2,5 wochen zeit bis sie das geld überweisen. bin fast aus dem speku zeitraum.

hab nicht lust steuern zu zahlen weil mdt die übernahme so schnell durchzieht. ursprünglich war doch von anfang 2008 die rede

[Larry.Livingston]

Wenn ich ganz kurz etwas einwerfen darf: ihr seid beide beim gleichen Broker, also wirds da kaum Unterschiede in der Gutschriftsbuchung geben.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.370.555 von Larry.Livingston am 09.11.07 22:06:45

yep, Larry, so wirds wohl sein, habs echt nicht geblickt..
Ja, pontius, ist natürlich ärgerlich für Dich, wenn Du noch in den Spekuzeitraum fällst. ich kann mir eigentlich nicht vorstellen, dass es noch so lange dauert, aber wer weiss. ich habe mit so ner Aktion keine Erfahrung, aber Simonswald müsste das evtl wissen, dessn Numico wurde ja auch geschluckt.

Okay, schönen Abend noch
Gruss space